BioSpace News Archive

Favorable patient outcomes from the TANDEM I first-in-human clinical trial of the CroíValve DUO™ System for the percutaneous treatment of tricuspid regurgitation (TR) were presented today by Professor Wojciech Wojakowski at the New York Valves 2024 scientific conference.

Ashvattha Therapeutics announced the presentation of data demonstrating the therapeutic potential of Ashvattha’s novel CSF1R dendranib for MS based on symptom reduction in a mouse experimental autoimmune encephalitis model.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced positive preclinical study results highlighting the potential efficacy and safety profile of Ketamir-2, MIRA’s novel oral ketamine analog designed to treat depression and treatment-resistant depression (TRD).

ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced a strategic license agreement with Roche for use of the ALZpath pTau217 antibody to develop and commercialize an Alzheimer’s disease diagnostic blood test that will be offered on the Roche Elecsys® platform.

Actinium Pharmaceuticals, Inc., a leader in the development of Antibody Radiation Conjugates and other targeted radiotherapies, highlighted data from multiple abstracts that were presented at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the completion of enrollment as well as positive initial data from the ongoing Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).

In a strategic move that could reshape the understanding of long COVID and chronic Lyme disease, the Massachusetts Institute of Technology has forged a partnership with Movano Health for its MAESTRO study to harness the medical grade continuous health monitoring capabilities of Movano’s Evie Ring.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

Adolore BioTherapeutics, a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies